VA Dramatically Reduces ESA Use for Cancer-Related Anemia

COLUMBIA, SC -- Erythropoiesis-stimulating agents were indicated for use in patients with cancer who receive noncurative myelosuppressive chemotherapy, with the intention of mitigating symptoms and side effects to decrease the need for red blood cell transfusions....

Is Radiation Therapy Linked to Second Cancer Diagnoses?

STANFORD, CA – How likely is a second cancer diagnosis after primary cancer treatment with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), or proton beam radiotherapy (PBRT) for lymphoma and other cancers? Researchers from...

Changes in Myelofibrosis Survival at VA

HOUSTON — Myelofibrosis Is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is classified as a myeloproliferative neoplasm (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally....

CLL Treatments Shift Significantly at VHA From 2013-2018

DENVER, CO – Since the first novel agent was approved for use in chronic lymphocytic leukemia patients in 2014, how have treatment regimens changed at the VHA? That was the question behind a presentation at the recent 2020 American Society of Clinical Oncologists...